Table 2.
IPTW-weighted univariate and multivariate Cox regression analyses for progression-free survival (PFS)
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Sex Men (R) Women |
1.145 (0.822-1.594) | 0.423 | 1.144 (0.790-1.657) | 0.475 |
| Age <65 (R) ≥65 |
1.627 (1.158-2.286) |
0.005 |
1.857 (1.226-2.812) |
0.003 |
| ECOG 0 (R) 1 |
1.039 (0.749-1.443) | 0.818 | 0.916 (0.612-1.372) |
0.671 |
| Comorbidity No (R) Yes |
0.952 (0.683-1.325) | 0.769 | ||
| Tumor location Right-sided colon (R) Left-sided colon Rectum |
0.830 (0.561-1.227) 0.810 (0.515-1.273) |
0.350 0.361 |
||
| Tumor presentation De novo metastasis (R) Metachronous metastasis |
0.846 (0.534-1.341) |
0.478 |
||
| RAS/BRAF mutation status Wild-type (R) Mutant |
1.163 (0.817-1.656) |
0.401 |
1.142 (0.806-1.620) |
0.455 |
| Liver metastasis No (R) Yes |
1.513 (1.012-2.263) |
0.043 |
1.758 (1.176-2.629) |
0.006 |
| Lung metastasis No (R) Yes |
1.024 (0.722-1.453) | 0.895 |
|
|
| Peritoneal metastasis No (R) Yes |
1.276 (0.696-2.340) | 0.431 |
|
|
| Bone metastasis No (R) Yes |
1.778 (1.100-2.875) | 0.019 | 2.208 (1.276-3.820) |
0.005 |
| Non-regional lymph node metastasis No (R) Yes |
0.814 (0.537-1.232) | 0.330 | ||
| Any-grade toxicity No (R) Yes |
1.129 (0.801-1.592) | 0.488 | ||
| Grade 3-4 toxicity No (R) Yes |
0.839 (0.588-1.197) | 0.333 | ||
| Treatment discontinuation due to toxicity Yes (R) No |
1.103 (0.789-1.540) | 0.567 | ||
| Dose reduction due to toxicity Yes (R) No |
1.021 (0.713-1.461) | 0.911 | ||
| Treatment Bevacizumab (R) Aflibercept |
1.302 (0.929-1.825) | 0.125 | 1.347 (0.960-1.889) |
0.085 |
ECOG: Eastern Cooperative Oncology Group